It is indicated in gastrointestinal diseases and disorder diabetic gastroparesis.
GIP has dual mode of action where it increases acetylcholine concentrations by inhibiting dopamine D2 receptors and acetylcholinesterase. Higher acetylcholine increases GI peristalsis, increases the lower esophageal sphincter pressure, stimulates gastric motility, accelerates gastric emptying, and improves gastro-duodenal coordination.
Rapid and extensive absorption (96% - 98%). The peak serum concentrations are achieved within 35 minutes after oral dosing. GIP is readily and extensively distributed except in the central nervous system and spinal cord. The drug is metabolized in the liver by N-oxidation to inactive metabolites by the enzyme flavin-containing monoxygenase. Half-life: 6 hours The pharmacokinetic profile after repeated doses is similar to that after the first dose. Food does not significantly affect the absorption of GIP.
Oral Antiemetic, Prokinetic agent Adult: 150mg OD. Reduce dose depending on the patient’s age and symptoms. Food (before/after) Should be taken on an empty stomach (i.e. At least one hour before food or two hours after food).